The independent controls segment by product is estimated to lead the market growth during the forecast period.
According to a new market research study of “Europe Molecular Quality Controls Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, Analyte Type, Application, End-user and Country.” The Europe molecular quality controls market is expected to reach US$ 109.59 million by 2028 from US$ 55.76 million in 2021; it is estimated to grow at a CAGR of 10.1% from 2021 to 2028. The report highlights trends prevailing in the Europe molecular quality controls market and the factors driving market along with those that act as hindrances.
The Europe molecular quality controls market, by product, is segmented into independent controls and instrument specific controls. The independent controls segment held the largest share of the market in 2020 whereas the same is anticipated to register the highest CAGR in the market during the forecast period.
The Europe molecular quality controls market is expected to reach US$ 109.59 million by 2028 from US$ 55.76 million in 2021; it is estimated to grow at a CAGR of 10.1% from 2021 to 2028. Factors such as growing funds for genomics, declining cost of sequencing procedures, and increasing prevalence of genetic diseases fuel the growth of the market. However, the dearth of skilled professionals hinders the market growth.
Genome sequencing has now become one of the common techniques in clinical practices. As per the study ‘Integrating Genomics into Healthcare’, over the next a few years, the healthcare sector is expected to generate genomic data of over 60 million patients. The growing implementation of genomic sequencing in healthcare systems is supported by substantial government investments, totaling over US$ 4 billion by at least 14 countries. The UK announced world’s largest genome project as a part of 200 million public-private collaboration between charitable organizations and pharmaceutical companies. Led by Innovate UK, a part of UK Research and Innovation, the project was initiated to support researchers and industries through funds to combine data and real-world evidence obtained from health services in the UK as well as to create new products and services for more efficient and early disease diagnosis. Such continuous funding by the manufacturers and governments in the field of genomics is supporting the growth of the molecular quality controls market. Also, the cost of genome sequencing, as well as next-generation sequencing, has dropped radically in the past 6-7 years. Moreover, the process requires a lesser number of days for completion. Lowering costs and accelerating overall process enable service providers to secure larger profit margins, along with helping them expand their clientele. Thus, the lowered cost of genome sequencing is propelling the number of molecular biology procedures carried out for different purpose, thereby driving the use of molecular quality controls.
The European region is highly affected by the outbreak of the COVID-19 pandemic. The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Molecular quality controls is a used in the process for R&D. The rising numbers of product launches in 2020 and rising incidence of COVID-19 has positive impacted in the Europe molecular quality controls market. For instance, UK based Launch Diagnostics introduced AmpliRun and AmpliRun total coronavirus molecular controls for in vitro diagnostic techniques based on nucleic acid amplification. AmpliRun Total is used for external quality control for nucleic acids detection in Europe.
Factors such as growing funds for genomics, declining cost of sequencing procedures, and increasing prevalence of genetic diseases fuel the growth of the market. However, the dearth of skilled professionals hinders the market growth.
THERMO FISHER SCIENTIFIC INC. BIO-RAD LABORATORIES INC. HOFFMANN-LA ROCHE LTD. Abbott, Quidel Corporation, Qnostics, Maine Molecular Quality Controls Inc. Zeptometrix Corporation, Microbiologics, and Seracare Life Sciences are among the leading companies operating in the Europe molecular quality controls market.
The Europe molecular quality controls market, by product, is segmented into independent controls and instrument specific controls. The independent controls segment held the largest share of the market in 2020 whereas the same is anticipated to register the highest CAGR in the market during the forecast period.
The Europe molecular quality controls market is expected to reach US$ 109.59 million by 2028 from US$ 55.76 million in 2021; it is estimated to grow at a CAGR of 10.1% from 2021 to 2028. Factors such as growing funds for genomics, declining cost of sequencing procedures, and increasing prevalence of genetic diseases fuel the growth of the market. However, the dearth of skilled professionals hinders the market growth.
Genome sequencing has now become one of the common techniques in clinical practices. As per the study ‘Integrating Genomics into Healthcare’, over the next a few years, the healthcare sector is expected to generate genomic data of over 60 million patients. The growing implementation of genomic sequencing in healthcare systems is supported by substantial government investments, totaling over US$ 4 billion by at least 14 countries. The UK announced world’s largest genome project as a part of 200 million public-private collaboration between charitable organizations and pharmaceutical companies. Led by Innovate UK, a part of UK Research and Innovation, the project was initiated to support researchers and industries through funds to combine data and real-world evidence obtained from health services in the UK as well as to create new products and services for more efficient and early disease diagnosis. Such continuous funding by the manufacturers and governments in the field of genomics is supporting the growth of the molecular quality controls market. Also, the cost of genome sequencing, as well as next-generation sequencing, has dropped radically in the past 6-7 years. Moreover, the process requires a lesser number of days for completion. Lowering costs and accelerating overall process enable service providers to secure larger profit margins, along with helping them expand their clientele. Thus, the lowered cost of genome sequencing is propelling the number of molecular biology procedures carried out for different purpose, thereby driving the use of molecular quality controls.
The European region is highly affected by the outbreak of the COVID-19 pandemic. The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Molecular quality controls is a used in the process for R&D. The rising numbers of product launches in 2020 and rising incidence of COVID-19 has positive impacted in the Europe molecular quality controls market. For instance, UK based Launch Diagnostics introduced AmpliRun and AmpliRun total coronavirus molecular controls for in vitro diagnostic techniques based on nucleic acid amplification. AmpliRun Total is used for external quality control for nucleic acids detection in Europe.
Factors such as growing funds for genomics, declining cost of sequencing procedures, and increasing prevalence of genetic diseases fuel the growth of the market. However, the dearth of skilled professionals hinders the market growth.
THERMO FISHER SCIENTIFIC INC. BIO-RAD LABORATORIES INC. HOFFMANN-LA ROCHE LTD. Abbott, Quidel Corporation, Qnostics, Maine Molecular Quality Controls Inc. Zeptometrix Corporation, Microbiologics, and Seracare Life Sciences are among the leading companies operating in the Europe molecular quality controls market.
The report segments in Europe Molecular Quality Controls Market as follows:
By Product
- Independent Controls
- Instrument Specific Controls
- PCR
- DNA Sequencing and NGS
By Analyte Type
- Single Analyte Controls
- Multi Analyte Controls
By Application
- Infectious Diseases
- Oncology
- Genetic Testing
- Other Applications
By End-user
- Clinical Laboratories
- Hospitals
- IVD Manufacturers & Contract Research Organizations
- Academic & Research Institutes
- Other End-users
By Country
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe molecular quality controls market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe molecular quality controls market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Molecular Quality Controls Market - Market Landscape
5. Molecular Quality Controls Market - Key Market Dynamics
6. Molecular Quality Controls Market - Europe Analysis
7. Molecular Quality Controls Market Analysis - By Product
8. Molecular Quality Controls Market - By Analyte Type
9. Molecular Quality Control Market Analysis - By Application
10. Molecular Quality Control Market Analysis - By End User
11. Molecular Quality Controls Market - Europe Analysis
12. Impact of COVID-19 Pandemic on Europe Molecular Quality Controls Market
13. Industry Landscape
14. Company Profiles
15. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Hoffmann-La Roche Ltd.
- Abbott
- Quidel Corporation
- Qnostics
- Maine Molecular Quality Controls Inc.
- Zeptometrix Corporation
- Microbiologics
- Seracare Life Sciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 168 |
| Published | July 2021 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 55.76 Million |
| Forecasted Market Value ( USD | $ 109.59 Million |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Europe |
